5th Next Generation Gene Therapy Vectors Summit

The 5th Next Generation Gene Therapy Vectors Summit will be held from July 29 to 31, 2025, at the Revere Hotel Boston Common in Boston, Massachusetts. This conference serves as the only specialized platform dedicated to rational vector design and engineering for both viral and non-viral gene therapy applications. Attendees will dive into advanced capsid and payload engineering, AI-driven vector design, immunogenicity reduction strategies, dose optimization, and cost-efficient manufacturing. The summit encourages close collaboration among R&D, regulatory, and business development leaders to accelerate preclinical success and streamline translation to the clinic.

Participants will gain insights from major developers such as Spark Therapeutics, Novartis, 4D Molecular Therapeutics, Apertura Gene Therapy, Dyno Therapeutics, and Coave Therapeutics, who will share strategies for capsid optimization, regulatory guidance, manufacturing solutions, and investor trends. This environment fosters meaningful engagement through expert-led discussions, case studies, and poster sessions focused on both technical innovation and strategic partnerships.

Highlighted Speakers:

• Daniel Cohen, Head of Vector Optimization, Spark Therapeutics

• Eric Kelsic, Co‑Founder & CEO, Dyno Therapeutics

• Jorge Santiago‑Ortiz, Senior Director, CMC, Apertura Gene Therapy

• Lolita Petit, Chief Scientific Officer, Coave Therapeutics

• Ralf Schmid, Associate Director – Pre‑Clinical Research, Novartis AG